The SONImage Study
NCT04125277 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2025-04-18
Summary
SONImage is a multicenter prospective imaging side study, in which a baseline FES-PET is added to conventional work up, in 100 patients with ER+ MBC who will receive endocrine treatment ± CDK 4/6 inhibition within the SONIA study (NCT03425838). SONImage will be executed in two Dutch centers: UMCG and Amsterdam UMC-location VUMC. The aim of the SONImage study is to (1) assess the relationship between FES/FDG-PET heterogeneity patterns at baseline and PFS for first-line endocrine treatment ± CDK 4/6 inhibition in ER+ MBC, and (2) to further improve that by developing a prediction model, within the SONIA study. This molecular imaging based multivariable prediction model may provide a unique measure of benefit of adding CDK 4/6 inhibition to first-line endocrine treatment, allowing patients and providers to weigh individual benefits and (long term) burden for optimized treatment decisions.
Conditions
Interventions
- OTHER
-
FES-PET scan, and possibly one additional visit for an FDG-PET
One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
Sponsors & Collaborators
-
Dutch Cancer Society
collaborator OTHER -
BOOG Study Center
collaborator OTHER -
The Netherlands Cancer Institute
lead OTHER
Principal Investigators
-
C. P. Schröder, MD, PhD · The Netherlands Cancer Institute
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-05
- Primary Completion
- 2025-07-31
- Completion
- 2025-07-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer
NCT00647790 ·Status: COMPLETED
-
Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
NCT04861077 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
NCT04316117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Role of PET/MRI in Predicting the Outcome of Definitive Chemoradiotherapy for Esophageal Cancer Patients
NCT05855278 ·Status: COMPLETED ·Phase: NA
-
D4 Choline Breast PET/CT
NCT04276272 ·Status: COMPLETED
-
4FMFES-PET Imaging of ER+ Advanced Breast Cancers
NCT04824014 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors
NCT07128277 ·Status: NOT_YET_RECRUITING
-
FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET
NCT03726931 ·Status: COMPLETED ·Phase: NA
-
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
NCT01916122 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
18F-AmBF3-TATE PET/CT for Imaging NET Patients
NCT04207762 ·Status: COMPLETED
-
FAPI PET/CT for Lymph Node Staging in Colorectal Carcinoma
NCT05209750 ·Status: UNKNOWN ·Phase: NA
-
Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer
NCT01627704 ·Status: COMPLETED ·Phase: NA
-
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
NCT04258592 ·Status: TERMINATED ·Phase: PHASE1
-
An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation
NCT01260480 ·Status: UNKNOWN ·Phase: PHASE2
-
Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer
NCT01986569 ·Status: COMPLETED ·Phase: PHASE3
-
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
NCT06082492 ·Status: RECRUITING ·Phase: NA
-
AR and ER Imaging in Metastatic Breast Cancer
NCT01988324 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer
NCT00358098 ·Status: TERMINATED
-
An Imaging Study in ER Negative Breast Cancer by Targeting αvβ6
NCT06978478 ·Status: WITHDRAWN ·Phase: NA
-
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
NCT03846167 ·Status: ACTIVE_NOT_RECRUITING
-
A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation
NCT00847509 ·Status: COMPLETED ·Phase: NA
-
Rectal Cancer: Local Staging, Re-staging and Assessment of Lymph Nodes Using Pet-Ct, CT-Perfusion and 3T MRI
NCT01525056 ·Status: COMPLETED ·Phase: PHASE2
-
Positron Emission Tomography in Patients With Breast Cancer
NCT00001385 ·Status: COMPLETED
-
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
NCT03544762 ·Status: UNKNOWN ·Phase: PHASE3
-
18F-FSPG PET/CT Imaging in Patients With Cancers
NCT03144622 ·Status: UNKNOWN